Vascular surgeons and researchers from the Mayo Clinic in Rochester, USA, and University of Tennessee at Chattanooga joined hands to compare outcomes of mesenteric angioplasty using percutaneous transluminal angioplasty and stenting with iCAST covered stents (Atrium) or bare metal stents in patients with chronic mesenteric ischaemia. Their findings were released at the 66th Vascular Annual Meeting presented by the Society for Vascular Surgery on 7 June 2012.
On 4 June 2012, Hansen Medical announced that it has received 510(k) clearance from the FDA for its Magellan Robotic System, including the catheter and accessories. The company will commence commercialisation at selected centres in the US immediately, with a full launch expected later in the year. The product will be presented at the 66th Vascular Annual Meeting of the Society for Vascular Surgery at National Harbor, from 7–9 June.
TriVascular announced on 4 June 2012 a US$60 million series D Preferred Stock equity financing commitment; the initial tranche of which closed on 1 June. New investor Kaiser Permanente Ventures, in partnership with the Redmile Group, led the round joining existing investors New Enterprise Associates, Delphi Ventures, MPM Capital, Kearny Venture Partners and Pinnacle Ventures. Sam Brasch, director at Kaiser Permanente Ventures, will join TriVascular’s Board of Directors.
W. L. Gore & Associates (Gore) today announced that the GORE® Hybrid Vascular Graft was awarded Gold Winner in the Implant and Tissue-Replacement Products category of the 2012 Medical Design Excellence Awards (MDEA) competition. The Gore Device is an expanded polytetrafluoroethylene (ePTFE) vascular prosthesis that provides a streamlined solution for challenging dialysis access, aortic debranching, and arterial bypass procedures. The award-winning prosthesis provides a new way in for better outflow and the potential to significantly improve patient outcomes.
Four-dimensional (4D) imaging techniques are available and can capture dynamic changes in blood flow and aortic morphology, and this type of technology can potentially be used for risk stratification and to guide treatment in individual patients undergoing endovascular thoracic aortic repair, Rachel Clough told delegates at the CX Symposium (14–17 April, London, UK).
MAQUET Cardiopulmonary, a business unit of MAQUET Cardiovascular and a leader in extracorporeal life support (ECLS) systems, today announced that they have signed an agreement with Avalon Laboratories to acquire its Avalon Elite® Bi-Caval Dual Lumen Catheter and complimentary vascular access kits for use during ECLS.
The Society for Vascular Surgery (SVS) and Gore have announced an initiative that recognises the contributions of female vascular surgeons and aims to advance the number of women entering the profession.
The Society for Vascular Surgery® (SVS) and W. L. Gore & Associates (Gore) today announced an initiative that recognizes the contributions of female vascular surgeons and aims to advance the number of women entering the profession. Currently women account for only seven percent of board certified vascular surgeons, yet cardiovascular disease remains the nation’s number one killer among women. In a video released today, Eva Rzucidlo, MD, Chair of the SVS Women’s Leadership Committee and Vascular Surgeon, Dartmouth/Hitchcock Medical Center, discusses the need for more female vascular surgeons with the rising number of women diagnosed with vascular-related diseases.
Ten generic versions of the anti-clotting drug clopidogrel (Plavix) were approved en masse by the FDA on Thursday, coinciding with the expiration of a key patent on the drug. Two dosage forms for the generics were approved: 300 mg, produced by Gate, Mylan, and Teva; and 75 mg, manufactured by Apotex, Aurobindo, Mylan, Roxane, Sun Pharma, Teva, and Torrent.
Twelve-month results from the BIOSOLVE-I study with the DRug Eluting Absorbable Metal Scaffold (DREAMS) demonstrate safety and confirm vessel vasomotion. T he results from the BIOSOLVE-I study were presented at the European Course on Revascularization in Paris (EuroPCR) by Professor Michael Haude, Lukaskrankenhaus, Neuss, Germany.
Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT) is expanding availability of the Valiant® Captivia® Thoracic Stent Graft System in several countries, including China, Japan and the United States. "The expanded offering of the Valiant Captivia Stent Graft in these major global markets epitomizes our commitment to globalization," said Tony Semedo, general manager of the Endovascular Therapies business unit at Medtronic. "Now, more physicians across the globe than ever before will be able to offer their patients a minimally-invasive treatment option for life-threatening thoracic aortic aneurysms without the associated trauma of open surgery."
Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focussed on innovative vascular products, announces that it has received feedback from the U.S. Food and Drug Administration (“FDA”) as a result of its 100 day review. This review is part of the process for the pre-market approval (“PMA”) application for AorfixTM, the Company’s flexible stent graft for the endovascular repair of abdominal aortic aneurysms (“AAAs”). As previously announced the PMA filing was accepted for review in January 2012.
The first-in-man experience results with a new bioresorbable scaffold for superficial femoral artery lesions were presented by Andrew Holden, Auckland, New Zealand, yesterday. Holden described the Stanza Bioresorbable Scaffold System from 480 Biomedical and initial case experience from the first patients treated in the STANCE trial.
La Sociedad Española de Arteriosclerosis (SEA) ha hecho hincapié en la necesidad de que los médicos de atención primaria tengan más protagonismo a la hora de detectar uno de los problemas de salud más importantes en España: las dislipemias. Según indicó el presidente de la SEA, Juan Pedro-Botet, “siguen estando infradiagnosticadas, infratatadas e infracontroladas”, por ello, añadió “el abordaje del riesgo vascular debe efectuarse de forma global y las actuaciones deben estar integradas en todos los niveles: poblacional, comunitario e individual”. Es aquí donde la participación de la atención primaria es imprescindible por su posición, proximidad y accesibilidad.
Five-year data from the THU"DER trial demonstrated a 59% relative reduction in target lesion revascularisation rates in popliteal arteries of patients with peripheral arterial disease (PAD) treated with the Cotavance drug-eluting balloon (Medrad) with Paccocath technology compared to standard balloon angioplasty. Additionally, for patients requiring target lesion revascularisation, the average time to revascularisation before target lesion revascularisation was extended by 448 days in patients treated with the Cotavance catheter.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos